

- (च) विनिर्माता या विपणन कम्पनी, उपरोक्त विनिर्मितियों और विनिर्दिष्ट शर्तों का पालन नहीं करती हैं तो वे आवश्यक वस्तुएँ अधिनियम, 1955 के साथ पठित डीपीसीओ, 2013 के प्रावधानों के अधीन ब्याज सहित अधिप्रभारित राशि को जमा करने के लिए उत्तरदायी होंगे।
- (छ) इस आदेश में उपरोक्त तालिका के कॉलम (3) और (5) में तत्स्थानी प्रविष्टियों में निर्दिष्ट विनिर्माण और विपणन कंपनियों की स्ट्रेंथ और नाम के साथ, उपरोक्त तालिका के कॉलम (2) में निर्दिष्ट ऐसे फॉर्मूलेशन के खुदरा मूल्य के निर्धारण के परिणामस्वरूप, कॉलम (2), (3) और (5) में तत्स्थानी प्रविष्टियों में यथा निर्दिष्ट उस विनिर्माण और विपणन कंपनियों के लिए निर्दिष्ट स्ट्रेंथ के साथ फॉर्मूलेशन के खुदरा मूल्य को निर्धारित करने वाले कोई मूल्य आदेश यदि इस अधिसूचना से पहले जारी किए गए हो, तो उसे इसका स्थान लिया माना जाएगा।

ORDER

New Delhi, the 6th August, 2024

S.O. 3170(E).— In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the Table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

TABLE

S. No.	Medicines	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(3)	(4)	(5)	(6)	(7)
1.	Telmisartan and Chlorthalidone Tablet	Each uncoated bilayered tablet contains: Telmisartan IP 40mg Chlorthalidone IP 6.25mg	1 Tablet	M/s Innova Captab Ltd./ M/s Corona Remedies Pvt. Ltd.	5.80
2.	Dapagliflozin, Vildagliptin (SR) and Metformin Hydrochloride (SR) Tablets	Each uncoated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin IP 100mg (As Sustained release from) Metformin Hydrochloride IP 500mg (as Sustained Release from)	1 Tablet	M/s Mascot Health Series Pvt. Ltd. / M/s Macleods Pharmaceuticals Ltd.	13.17
3.	Dapagliflozin, Sitagliptin and Metformin Hydrochloride (Extended release) Tablets	Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Metformin Hydrochloride IP 500mg (as extended release)	1 Tablet	M/s Synokem Pharmaceuticals Limited / M/s Unison Pharmaceuticals Pvt. Ltd.	10.27
4.	Dapagliflozin, Sitagliptin and Metformin Hydrochloride (Extended release) Tablets	Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg	1 Tablet	M/s Synokem Pharmaceuticals Limited / M/s Unison Pharmaceuticals Pvt. Ltd.	11.16

		Metformin Hydrochloride IP 1000mg (as extended release)			
5.	Teneligliptin, Dapagliflozin & Metformin Hydrochloride (Sustained Release) Tablets	Each film coated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate IP eq. to Teneligliptin 20mg Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 500mg (As Sustained Release)	1 Tablet	M/s Synokem Pharmaceuticals Ltd. / M/s Glenmark Pharmaceuticals Limited	12.15
6.	Teneligliptin, Dapagliflozin & Metformin Hydrochloride (Sustained Release) Tablets	Each film coated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate IP eq. to Teneligliptin 20mg Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 1000mg (As Sustained Release)	1 Tablet	M/s Synokem Pharmaceuticals Ltd. / M/s Glenmark Pharmaceuticals Limited	13.39
7	Sitagliptin and Metformin Hydrochloride Tablets	Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg	1 Tablet	M/s Corona Remedies Pvt. Ltd.	12.41
8	Sitagliptin and Metformin Hydrochloride (ER) Tablets	Each film coated bilayered tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Metformin Hydrochloride IP 1000mg (As Extended Release form)	1 Tablet	M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Corona Remedies Pvt. Ltd.	14.20
9	Sitagliptin and Metformin Hydrochloride Tablets	Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 500mg	1 Tablet	M/s Corona Remedies Pvt. Ltd.	6.49
10	Sitagliptin and Metformin Hydrochloride (ER) Tablets	Each film coated tablet contains: Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100mg Metformin Hydrochloride (as Extended Release) IP 500mg	1 Tablet	M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Corona Remedies Pvt. Ltd.	13.30
11	Dapagliflozin, Sitagliptin and Metformin Hydrochloride (as Extended Release) Tablets	Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Sitagliptin Phosphate IP eq. to Sitagliptin 100mg	1 Tablet	M/s Mascot Health Series Pvt. Ltd. / M/s Macleods Pharmaceuticals Ltd.	15.89

		Metformin Hydrochloride (as Extended Release) IP 500mg			
12	Dapagliflozin, Sitagliptin and Metformin Hydrochloride (as Extended Release) Tablets	Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Sitagliptin Phosphate IP eq. to Sitagliptin 100mg Metformin Hydrochloride (as Extended Release) IP 1000mg	1 Tablet	M/s Mascot Health Series Pvt. Ltd. / M/s Macleods Pharmaceuticals Ltd.	17.50

[PN/257/125/2024/F/F. No. 8(125)/2024/D.P./NPPA-Div.-II]

MAHAVEER SAINI, Dy. Director

Note:

- The manufacturer of above-mentioned formulations i.e. “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
- The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
- In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.

आदेश

नई दिल्ली, 6 अगस्त, 2024

का.आ. 3171(अ).— भारत सरकार के रसायन और उर्वरक मंत्रालय द्वारा जारी का. आ. 1394 (अ) तारीख 30 मई, 2013 और का. आ. 5249(अ) तारीख 11 नवम्बर, 2022 के साथ पठित औषधि (मूल्य नियंत्रण) आदेश, 2013 के पैरा 5, 11 और 15 द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, राष्ट्रीय औषध मूल्य निर्धारण प्राधिकरण (जिसको संक्षिप्त रूप में एनपीपीए कहा जाता है), नीचे की सारणी के स्तंभ (6) में विनिर्दिष्ट खुदरा मूल्य को उक्त सारणी के स्तंभ (3), (4) और (5) में तत्स्थानी प्रविष्टियों में विनिर्दिष्ट प्रबलता, इकाई (यूनिट) और विनिर्माता और विपणन कंपनियों के नाम सहित स्तंभ(2) में की तत्स्थानी प्रविष्टि में से प्रत्येक की, वस्तु एवं सेवा कर, यदि कोई है, को छोड़कर अधिकतम खुदरा मूल्य के रूप में नियत करती है।